(Q39663467)

13 September 2017

title

Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo (English)

1 reference

13 September 2017

Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr–Abl positive cell lines in vitro and in vivo (English)

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

23 June 2024

5

Xiangyan Li

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739063

23 June 2024

author name string

Xia Yuan

1

1 reference

13 September 2017

Yi Zhang

2

1 reference

13 September 2017

Haijing Zhang

3

1 reference

13 September 2017

Jing Jin

4

1 reference

13 September 2017

He Liu

6

1 reference

13 September 2017

Zhiqiang Feng

7

1 reference

13 September 2017

Xiaoguang Chen

8

1 reference

13 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20739063

23 June 2024

publication date

23 August 2010

1 reference

full work available at URL

13 September 2017

https://api.elsevier.com/content/article/PII:S014521261000384X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

https://api.elsevier.com/content/article/PII:S014521261000384X?httpAccept=text/plain

23 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

23 June 2024

1 reference

13 September 2017

volume

35

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

237-242

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

13 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

The BCR-ABL story: bench to bedside and back

23 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

23 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

23 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

23 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Resistance to imatinib mesylate in chronic myeloid leukaemia

23 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Chronic myeloid leukemia in 2006: a perspective

23 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

23 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

23 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase

23 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice

23 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Overriding imatinib resistance with a novel ABL kinase inhibitor

23 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro

23 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

23 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

23 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

23 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

23 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

23 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

23 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

23 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

23 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

23 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

23 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Src kinase signaling in leukaemia

23 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells

23 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils

23 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

23 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition

23 June 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.041

23 June 2024

Identifiers

1 reference

13 September 2017

1 reference